NCT00305604View on ClinicalTrials.gov

Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

March 8, 2006

Primary Completion Date

March 12, 2008

Study Completion Date

March 12, 2008

Conditions
Type 2 Diabetes
Interventions
DRUG

sitagliptin phosphate

Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.

DRUG

Comparator: Placebo

sitagliptin matching placebo for up to a 24-wk treatment period.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00305604 - Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED) | Biotech Hunter | Biotech Hunter